CER-001 Atherosclerosis Regression ACS Trial; A Phase II Multi-Center, Double-Blind, Placebo-Controlled, Dose-Focusing Trial Of Cer-001 In Subjects With Acute Coronary Syndrome

Trial Profile

CER-001 Atherosclerosis Regression ACS Trial; A Phase II Multi-Center, Double-Blind, Placebo-Controlled, Dose-Focusing Trial Of Cer-001 In Subjects With Acute Coronary Syndrome

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Feb 2017

At a glance

  • Drugs CER 001 (Primary)
  • Indications Acute coronary syndromes
  • Focus Therapeutic Use
  • Acronyms CARAT
  • Sponsors Cerenis Therapeutics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 30 Jan 2017 Status changed from active, no longer recruiting to completed.
    • 19 Jan 2017 This trial has been completed in Hungary (end date: 30 Nov 2016).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top